Health ❯ Medicine ❯ Clinical Research ❯ Phase III Trials
The aldosterone‑synthesis inhibitor cut systolic readings by roughly 9–10 mmHg versus placebo in the BaxHTN trial, prompting plans for regulatory submissions.
